Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Acipimox is the active ingredient of these drugs:
Netherlands New Zealand Singapore South Africa United Kingdom
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):